After disappointing results of a phase II trial of imatinib mesylate, a recent single arm phase II study on another Receptor Tyrosine Kinase (RTK) inhibitor targeting PDGFR and VEGFR, sunitinib malate, demonstrated partial activity in recurrent and progressive Grade II and III meningiomas, encouraging additional trials [30]. The gene discussed is KDR; the disease is meningioma.